AL-ADTRAN
Adtran today launched its FSP 3000 Edge OLS, an open line system designed for the new generation of coherent edge access, aggregation and metro networks. It enables operators to efficiently address soaring bandwidth demand from mobile, broadband and enterprise applications by leveraging the latest coherent pluggable technology in this cost-sensitive part of the network. The FSP 3000 Edge OLS has been specifically engineered for the use of coherent transmission at the optical edge, including the recently introduced Coherent 100ZR, as well as 400ZR optics. By utilizing power-optimized wavelength broadcasting technology and a gridless architecture, the solution enables a simple and affordable optical layer with compact and flexible nodes that can transport any coherent signal and baud rate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005466/en/
Adtran’s FSP 3000 Edge OLS will help operators deploy coherent optical edge networks in the most effective way possible. (Graphic: Business Wire)
“At OFC, we showcased our world-first QSFP28 Coherent 100ZR, bringing robust, efficient and simple coherent technology to the edge of the network. Now we’re complementing this innovative transceiver with an OLS optimized for the cost-efficient transport of coherent technology at the optical edge. Providing maximum performance, it meets all critical demands of edge aggregation networks, including scalability, compact design, low power consumption, operational simplicity and extended temperature operation for outdoor deployment,” said Christoph Glingener, CTO at Adtran. “Our pioneering work at the network edge is creating whole new opportunities for service providers.”
The Adtran FSP 3000 Edge OLS is an open line system engineered to help operators roll out coherent optical edge networks in the most cost-effective and flexible way possible. With ZR-optimized technology for minimal insertion loss, the new OLS enables the use of ZR coherent optics at the optical edge in multiple use cases, including linear, hub-and-spoke or tree topologies. With its modular design, it empowers users to mix and match elements to create a solution that meets their exact needs. What’s more, the Adtran FSP 3000 Edge OLS facilitates the development of a compact and efficient optical layer with low-power nodes that require minimal space and can function in an extended temperature range. This enables deployment in outdoor environments, such as street cabinets.
“Our FSP 3000 Edge OLS offers a major boost to operators looking for an affordable way to tackle relentless growth in data traffic. Low-cost yet highly flexible, it can scale to transparently accommodate any line speed or baud rate. Now there’s a clear route to deploying an optical layer that leverages coherent transport technology, including 100ZR and 400ZR optics, and meets the stringent requirements of the new optical edge,” commented Henning Hinderthür, VP of product line management, Optical Networks at Adtran. “Our FSP 3000 Edge OLS harnesses advanced wavelength broadcast technology for new levels of power and cost efficiency. It’s also ready to be deployed anywhere from central offices to street furniture.”
Further details on Adtran’s FSP 3000 Edge OLS are available in these slides.
A supporting product video is available to watch.
A solution brief can also be downloaded.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom